Diary - News All news Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep continues to consolidate its position as a leading CDMO for the production of
innovative and targeted molecules to treat cancer by investing in additional capacity
Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
More than 30 full-time jobs to be created

Lyon, France – May 12, 2021 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce today a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities on its Le Mans (72 – France) site. This new step underlines customers' confidence in Novasep’s expertise in HPAPIs & ADCs and reinforces Novasep’s position as a leading CDMO for the production of innovative and targeted molecules to treat cancer.